S_mury Plasma level. plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy. Three additional patients had the production rate of oestrone sulphate investigated. Plasma oestrone and oestrone sulphate levels were reduced by a mean of 46% (P<O.05) and 71% (P<0.005) respectively. These alterations were due to a combined action of aminoglutethimide inhibiting oestrogen production but also increasing oestrogen metabolism. While oestrone and oestrone sulphate production rate was reduced by a mean of 31% (P<0.05) and 41% (P<0.005) respectively, the plasma clearance rate of oestrone was found to be increased by a mean of 30% (P<0.05), and the plasma clearance rate of oestrone sulphate was increased by a mean of 112% during aminoglutethimide treatment. The fraction of oestrone sulphate converted into plasma oestrone was reduced by 52% (P<0.05), the transfer of circulating oestrone into oestrone sulphate was non-significantly reduced by a mean of 16%. The findings in this investigation show that aminoglutethimide treatment influences oestrogen disposition by mechanisms unrelated to aromatase inhibition. The possibility that such effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast cancer should be considered.
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Aminoglutethimide is a drug successfully used for endocrine treatment of breast cancer . It is thought to act by inhibiting oestrogen production in post-menopausal women. The major oestrogen production pathway in nonmenstruating women is peripheral conversion of A4-androstenedione into oestrone (Grodin et al., 1973) , and aminoglutethimide is thought to act through an efficient inhibition of the aromatase enzyme (Thompson & Siiteri, 1974) . In vivo investigations have shown oestrone production from androstenedione to be inhibited by 95% in patients on aminoglutethimide treatment (Santen el al., 1978) . However, patients receiving aminoglutethimide treatment seem to have sustained oestradiol as well as oestrone plasma levels about 50% of their pretreatment values (Dowsett et al., 1985; Harris et al., 1983; Newsome et al., 1978; Santen et al., 1982; Vermeulen et al., 1983) . The possibility that oestrogens may be produced by pathways other than aromatisation of androstenedione has been suggested (Kirschner et al., 1978; Longcope et al., 1982; Reed et al., 1986) . The question whether it is possible to inhibit oestrogen production completely by aromatase inhibition remains open.
Aminoglutethimide is a potent inducer of certain hepatic mixed function oxydases, increasing the metabolism of several drugs in man (L0nning et al., 1984, 1986) . In previous studies we found aminoglutethimide to stimulate the metabolism of oestrone sulphate (L0nning et al., 1987) and increase urinary excretion of oestrogen metabolites produced by mixed function oxidations (L0nning & Skulstad, 1989) . It has been suggested that oestrone sulphate is an important precursor of intracellular oestradiol (Santner et al., 1984 (Santner et al., , 1986 , an increased metabolism of this oestrogen might reduce tumour oestrogen exposition. The present study was initiated to measure plasma oestrone and oestrone sulphate production rate in patients receiving aminoglutethimide treatment to evaluate (1) the reduction in oestrone and oestrone sulphate production rate, and (2) (Lonning et al., 1987) . These patients had blood samples obtained on the morning of their steroid injections, from which plasma oestrogens could be measured, and the oestrone sulphate production rate could be calculated.
All patients except S. , 1986) . The steroid injection technique, the blood sampling protocol and the labelled oestrogen analysis were as described previously (L0nning et al., 1987) . Blood samples (20 ml) were drawn at 8 a.m. for plasma oestrone and oestrone sulphate determination. The patients then received their tracer oestrogens as a min bolus injection, and heparinised blood samples (10ml) were drawn through an indwelling needle at 5, 10, 15, 22.5, 30, 45, 60, 90, 120, 150, 180, 210, 240, 300, 360, 480 , 600, 720 and 900min. All samples were centrifuged, plasma separated and stored at -20°C until analysis.
Oestrogen measurement Plasma oestrone, plasma oestrone sulphate and plasma tracer oestrogen concentrations were measured by methods previously descnrbed (Lonning et al., 1987 (Lonning et al., , 1989 . Samples from each patient were analysed in the same batch. The intra-assay coefficients of variation for radiolabelled oestrone and oestrone sulphate were 6.9% and 8.5% respectively. For plasma oestrogen analysis, intra/inter assay coefficients of variation for oestrone and oestrone sulphate were 8/12% and 7/9% respectively.
Measurement of aminoglutethimnide in serum
Serum obtained 3 and 12h following tracer injections were analysed for aminoglutethimide. The mean value of these two determinations were interpreted as a steady state serum level. Aminoglutethimide was determined by the method of Schanche et al. (1984) .
The three patients (B.V., S.P. and K.M.) who had their oestrone sulphate clearance determined previously were found to have aminoglutethimide plasma levels in the normal range for patients on steady state treatment with that drug schedule (Lonning et al., 1985 (Lonning et al., , 1987 .
Pharmacokinetic calculations
The metabolic clearance rate of oestrone and oestone sulphate were calculated from the equation:
where dose is the amount of the respective tracer administered and AUC the area under its elimination curve.
In a previous study, we found that oestradiol kinetics could be well fitted to a 3-compartmental model, while the kinetics of oestrone sulphate did not fit into a simple 2-or 3-compartment open model, most probably because of its enterohepatic circulation (L0nning et al., 1987 (Harris et al., 1984; Roberts et al., 1980; Samojlik et al., 1977; Vermeulen et al., 1978) . The clearance and production rates for oestrone in our patients were in the lower range. but consistent with results reported previously for breast cancer patients and normal postmenopausal women (Judd et al., 1982; Kirschner et al., 1978; Longcope & Williams, 1974; Reed et al., 1986) . The plasma clearance of oestrone sulphate was similar to values found by us in a previous investigation (L0nm 'ng et al., 1987) , the oestrone sulphate production rate was found somewhat lower than values reported for young men and menstruating women in the follicular phase of cyclus (Longcope, 1972; Ruder et al., 1972 (Noel et al., 1979) . One study has suggested a diurnal variation of oestrone in men (Baird & Guevara, 1969 (Longcope, 1972; Ruder et al., 1972) . In this study we found aminoglutethimide treatment to depress plasma oestrone and oestrone sulphate to about 55% and 30% of their control levels. consistent with previous findings by us (L0nning et al., 1989) and others (Harris et al., 1983; Santen et al., 1982; Vermeulen et al., 1983) . The finding that aminoglutethimide treatment causes a 112% increase in the metabolic clearance rate of oestrone sulphate is similar to our previous findings (L0nning et al., 1987) .
The clearance rate of oestrone during aminoglutethimide treatment was reported by Santen et al. (1978) (Santen et al., 1978) . As oestrone sulphate has a half-life about 6 h, there may be doubts whether oestrone steady state levels are reached by such short-term infusions (Hembree et al., 1969 & Kvinnsland, 1988) . The discrepancy may be due to a different metabolic clearance rate of the two oestrogens. Oestradiol is a so-called 'highly extracted compound' (Wilkinson & Shand, 1975 ) with a clearance rate exceeding hepatic plasma flow (Longcope et al., 1968 (Longcope & Williams, 1974) , it may be surprising to find that oestrone clearance rate is increased by aminoglutethimide treatment. However, an explanation may be found in the reduced conversion of oestrone sulphate back to oestrone (fmo,,s<o1,) . While 1-2% of circulating oestrone sulphate will be converted into plasma oestradiol (Ruder et al., 1972) , 18-45% of circulating oestrone sulphate was converted into plasma oestrone in our patients. Therefore. a considerable amount of oestrone converted into oestrone sulphate will be reconverted into plasma oestrone. In a previous investigation we found the fraction of oestradiol converted into oestrone sulphate to be reduced by aminoglutethimide treatment (L0nning et al., 1987) . In this investigation we found aminoglutethimide to reduce the fraction of oestrone converted into plasma oestrone sulphate as well as the fraction of oestrone sulphate converted into plasma oestrone. These findings are probably due to an increased intracellular metabolism of oestrogens (Lonning & Kvinnsland, 1988 ). An increased metabolic clearance rate of oestrone sulphate with a reduced conversion of oestrone sulphate to oestrone may result in an increase in plasma oestrone clearance rate.
A moderate reduction in the production rate of oestrone and oestrone sulphate of 30.7% and 41.0% contrasts with previous findings of a 95% inhibition of the aromatase reaction (Santen et al., 1978) . However, in recent years the hypothesis that post-menopausal oestrogen production does occur by peripheral aromatisation of androstenedione only has been challenged (Kirschner et al., 1978 : Longcope et al., 1982 Reed et al., 1986) . Our results indirectly support a theory that oestrogen production pathways other than the aromatisation of androstenedione into oestrone may be intact in patients receiving aminoglutethimide treatment.
The findings in this paper focus on the mechanism of action of aminoglutethimide in the treatment of breast cancer. The successful use of this drug for breast cancer treatment has prompted the development of new aromatase inhibitors undergoing current investigations (Goss et al., 1986) . It has been a concept for 10 years that aminoglutethimide depresses plasma oestrogens by inhibiting the peripheral production of oestrone from androstenedione only Santen et al., 1978) . Obviously, any other mechanism by which aminoglutethimide may depress plasma oestrogens could be part of its mechanism of action.
Recently, we reported that aminoglutethimide stimulates oestrone sulphate metabolism (L0nning et al., 1987) and reduces the plasma oestrone sulphate oestrone ratio (L0nning et al., 1989) . If plasma oestrone sulphate is an important oestrogen source for breast tumours, an increased metabolism of this oestrogen may be of importance for the mechanism of action of aminoglutethimide. The results of this study suggest that stimulation of oestrone sulphate metabolism may be of equal importance to inhibition of the production rate as a mechanism lowering plasma oestrone sulphate levels. Also, it suggests that the same mechanism may contribute to plasma oestrone depression. Accordingly, our results question aromatase inhibition as the sole mechanism of action of aminoglutethimide.
The findings of this study also suggest that aminoglutethimide treatment does not cause a complete inhibition of post-menopausal oestrogen production, probably due to the existence of alternative production pathways not inhibited by this drug. Further studies on aromatase inhibitors should consider the total production rate of oestrogens as well as aromatase inhibition, to evaluate any possible influence of drug treatment on oestrogen disposition.
